Dr. Petter Bjornstad, MD
Claim this profileChildren's Hospital Colorado
Studies Diabetes Mellitus
Studies Contrast-induced Nephropathy
11 reported clinical trials
14 drugs studied
Affiliated Hospitals
Clinical Trials Petter Bjornstad, MD is currently running
Sotagliflozin
for Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D. One of the few T1D studies conducted to date showed that implementing an enhanced DKA prevention plan can reduce the risk of DKA associated with the SGLT2i sotagliflozin (SOTA) to very low levels. In the present study, a similar DKA prevention program will be used to carry-out a 3-year trial to test the kidney benefit of SOTA in 150 persons with T1D and moderate to advanced DKD. After a 2-month period, during which diabetes care will be standardized and education on monitoring and minimizing DKA implemented, eligible study subjects will be randomly assigned (50/50) to take one tablet of SOTA (200 mg) or a similarly looking inactive tablet (placebo) every day for 3 years followed by 2-months without treatment. Neither the participants nor the study staff will know whether a person was assigned to taking SOTA or the inactive tablet. Kidney function at the end of the study will be compared between the two treatment groups to see whether SOTA prevented kidney function loss in those treated with this drug as compared to those who took the inactive tablet. The DKA prevention program will include participant education, close follow-up with study staff, continuous glucose monitoring, and systematic ketone body self-monitoring with a meter provided by the study. If successful, this study will provide efficacy and safety data that could be used to seek FDA approval of SOTA for the prevention of kidney function decline in patients with T1D and DKD.
Recruiting1 award Phase 3
Semaglutide
for Type 1 Diabetes
This trial is testing semaglutide, a drug that helps with heart, kidney, and blood sugar health, in adults with type 1 diabetes. The drug has shown benefits for people with type 2 diabetes, but it is not yet approved for type 1 diabetes. Researchers want to see if it can provide similar health improvements for this new group. Semaglutide has been evaluated in numerous trials for its effectiveness in improving blood sugar levels and weight loss in type 2 diabetes.
Recruiting1 award Phase 37 criteria
More about Petter Bjornstad, MD
Clinical Trial Related1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Petter Bjornstad, MD has experience with
- Renal Biopsy
- Sotagliflozin
- Placebo
- Dapagliflozin
- Aminohippurate Sodium Inj 20%
- Semaglutide
Breakdown of trials Petter Bjornstad, MD has run
Diabetes Mellitus
Contrast-induced Nephropathy
Type 1 Diabetes
Diabetic Kidney Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Petter Bjornstad, MD specialize in?
Petter Bjornstad, MD focuses on Diabetes Mellitus and Contrast-induced Nephropathy. In particular, much of their work with Diabetes Mellitus has involved treating patients, or patients who are undergoing treatment.
Is Petter Bjornstad, MD currently recruiting for clinical trials?
Yes, Petter Bjornstad, MD is currently recruiting for 4 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Petter Bjornstad, MD has studied deeply?
Yes, Petter Bjornstad, MD has studied treatments such as Renal Biopsy, Sotagliflozin, Placebo.
What is the best way to schedule an appointment with Petter Bjornstad, MD?
Apply for one of the trials that Petter Bjornstad, MD is conducting.
What is the office address of Petter Bjornstad, MD?
The office of Petter Bjornstad, MD is located at: Children's Hospital Colorado, Aurora, Colorado 80238 United States. This is the address for their practice at the Children's Hospital Colorado.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.